Utility of RET mutant in diagnosis and treatment of melanoma
The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.
1. A method of determining or predicting aggressiveness of a melanoma cancer based on the presence or absence of a RET (REarranged during Transfection) mutation in a melanoma cell from a human subject having melanoma cancer or a human melanoma cell culture comprising:
detecting the presence of a RET G691S mutation in the melanoma cell from a human subject having melanoma cancer or a human melanoma cell culture; and
determining or predicting that the melanoma cancer is a more aggressive melanoma cancer if the RET G691S mutation is present in the melanoma cell than if the RET G691S mutation is not present in the melanoma cell.
2. The method of claim 1 , wherein the melanoma cancer is DM (desmoplastic melanoma), non-DM, metastatic, or primary.
3. The method of claim 1 , further comprising detecting a BRAF (V-raf murine sarcoma viral oncogene homolog B1) V600E mutation in the melanoma cell.
4. The method of clam 3 , wherein the melanoma is DM, non-DM, metastatic, or primary.
5. The method of claim 1 , wherein the detection of a G691S RET mutation is accomplished by Southern blot, polymerase chain reaction (PCR), sequencing, a peptide nucleic acid-locked nucleic acid clamp method, Northern blot, reverse transcriptase-polymerase chain reaction (RT-PCR), immunohistochemistry or Western blot.
6. The method of claim 1 , wherein the aggressiveness of the melanoma cancer is determined by enhanced proliferation, more vigorous migration and more vigorous invasion of the melanoma cells when the RET mutation is present as compared to when the RET mutation is not present.